Research · Source update
REDEFINE 9 reports CagriSema weight-loss results
Source context: Read the linked original research or registry entry for study status and limitations.
Novo Nordisk provided topline Phase 3 results for investigational CagriSema in adults with excess weight. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Novo Nordisk provided topline Phase 3 results for investigational CagriSema in adults with excess weight. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Novo Nordisk REIMAGINE 5 and REDEFINE 9 announcement, dated 2026-09-21.
What did the source report?
The company reported 21% weight loss versus placebo at 68 weeks for the studied regimen. The REDEFINE 9 Phase 3 announcement reported 21% weight loss for CagriSema relative to placebo at 68 weeks in adults with overweight or obesity.
How should the results be interpreted?
This was a different trial from REIMAGINE 5, with a different participant population and comparator. The announcement summarized a separate trial from REIMAGINE 5; percentage reporting and comparators must not be mixed.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
CagriSema is a research product; reported efficacy is not marketing approval. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
CagriSema is a research product; reported efficacy is not marketing approval.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-09-21. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceNovo Nordisk REIMAGINE 5 and REDEFINE 9 announcement ↗
Source event or update: 2026-09-21. Our interpretation is educational and does not replace medical or insurance advice.